AbbVie (NYSE:ABBV) Shares Down 1.4% – Here’s Why

Shares of AbbVie Inc. (NYSE:ABBV) traded down 1.4% during trading on Monday . The stock traded as low as $222.39 and last traded at $222.9160. 3,989,737 shares were traded during trading, a decline of 37% from the average session volume of 6,347,647 shares. The stock had previously closed at $226.08.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research analyst reports. Evercore ISI boosted their price objective on AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a report on Monday, September 22nd. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Citigroup decreased their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating for the company in a research report on Monday, November 3rd. HSBC set a $225.00 price target on shares of AbbVie in a research note on Thursday, October 2nd. Finally, Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $241.85.

AbbVie Price Performance

The business has a 50-day simple moving average of $228.30 and a two-hundred day simple moving average of $208.54. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The stock has a market capitalization of $393.98 billion, a price-to-earnings ratio of 168.88, a P/E/G ratio of 1.22 and a beta of 0.36.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s payout ratio is 496.97%.

Institutional Trading of AbbVie

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Marshall & Sullivan Inc. WA bought a new stake in shares of AbbVie during the 2nd quarter worth $25,000. Evolution Wealth Management Inc. purchased a new stake in shares of AbbVie during the second quarter valued at $26,000. Chelsea Counsel Co. acquired a new position in shares of AbbVie in the 3rd quarter valued at $26,000. TD Capital Management LLC increased its stake in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after purchasing an additional 58 shares in the last quarter. Finally, Spurstone Advisory Services LLC acquired a new stake in AbbVie during the 2nd quarter worth about $28,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.